05:36 PM EDT, 08/19/2025 (MT Newswires) -- Kevin Joseph Fitzgerald, Chief Scientific Officer, Executive Vice President, and Head of Research, on August 15, 2025, sold 1,396 shares in Alnylam Pharmaceuticals ( ALNY ) for $632,759. Following the Form 4 filing with the SEC, Fitzgerald has control over a total of 23,256 common shares of the company, with 22,719 shares held directly and 537 controlled indirectly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1178670/000173527625000088/xslF345X05/edgardoc.xml